Our pipeline of high-value
product opportunities

LIFE-001 is advancing for the treatment of multiple immune-mediated disorders and organ transplant rejection.

LIFE-001 is a structurally and mechanistically novel, organ-sparing, immunophilin-independent calcineurin activation inhibitor (CNai) delivered as a long-acting injectable, being developed for the prevention of organ transplant rejection. Unlike currently available calcineurin inhibitors such as cyclosporin, voclosporin, and tacrolimus, LIFE-001 does not depend on intermediary immunophilin chaperone proteins and directly targets and binds calcineurin to keep it inactive and prevent T-cell activation and proliferation.

LIFE-001 has demonstrated compelling efficacy in preclinical models and has shown substantially improved safety over legacy calcineurin inhibitors. LIFE-001 is currently being evaluated in a first-in-human Phase 1 clinical trial with kidney transplantation and islet cell transplantation studies expected to begin in early 2027.